Ten years of external quality assessment (EQA) of Neisseria gonorrhoeae antimicrobial susceptibility testing in Europe elucidate high reliability of data.
EUCAST
Euro-GASP
European Union (EU)
European economic area (EEA)
Gonorrhoea
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
25 Mar 2019
25 Mar 2019
Historique:
received:
08
01
2019
accepted:
12
03
2019
entrez:
27
3
2019
pubmed:
27
3
2019
medline:
1
5
2019
Statut:
epublish
Résumé
Confidence in any diagnostic and antimicrobial susceptibility testing data is provided by appropriate and regular quality assurance (QA) procedures. In Europe, the European Gonococcal Antimicrobial Susceptibility Programme (Euro-GASP) has been monitoring the antimicrobial susceptibility in Neisseria gonorrhoeae since 2004. Euro-GASP includes an external quality assessment (EQA) scheme as an essential component for a quality-assured laboratory-based surveillance programme. Participation in the EQA scheme enables any problems with the performed antimicrobial susceptibility testing to be identified and addressed, feeds into the curricula of laboratory training organised by the Euro-GASP network, and assesses the capacity of individual laboratories to detect emerging new, rare and increasing antimicrobial resistance phenotypes. Participant performance in the Euro-GASP EQA scheme over a 10 year period (2007 to 2016, no EQA in 2013) was evaluated. Antimicrobial susceptibility category and MIC results from the first 5 years (2007-2011) of the Euro-GASP EQA were compared with the latter 5 years (2012-2016). These time periods were selected to assess the impact of the 2012 European Union case definitions for the reporting of antimicrobial susceptibility. Antimicrobial susceptibility category agreement in each year was ≥91%. Discrepancies in susceptibility categories were generally because the MICs for EQA panel isolates were on or very close to the susceptibility or resistance breakpoints. A high proportion of isolates tested over the 10 years were within one (≥90%) or two (≥97%) MIC log The high level of comparability of results in this EQA scheme indicates that high quality data are produced by the Euro-GASP participants and gives confidence in susceptibility and resistance data generated by laboratories performing decentralised testing.
Sections du résumé
BACKGROUND
BACKGROUND
Confidence in any diagnostic and antimicrobial susceptibility testing data is provided by appropriate and regular quality assurance (QA) procedures. In Europe, the European Gonococcal Antimicrobial Susceptibility Programme (Euro-GASP) has been monitoring the antimicrobial susceptibility in Neisseria gonorrhoeae since 2004. Euro-GASP includes an external quality assessment (EQA) scheme as an essential component for a quality-assured laboratory-based surveillance programme. Participation in the EQA scheme enables any problems with the performed antimicrobial susceptibility testing to be identified and addressed, feeds into the curricula of laboratory training organised by the Euro-GASP network, and assesses the capacity of individual laboratories to detect emerging new, rare and increasing antimicrobial resistance phenotypes. Participant performance in the Euro-GASP EQA scheme over a 10 year period (2007 to 2016, no EQA in 2013) was evaluated.
METHODS
METHODS
Antimicrobial susceptibility category and MIC results from the first 5 years (2007-2011) of the Euro-GASP EQA were compared with the latter 5 years (2012-2016). These time periods were selected to assess the impact of the 2012 European Union case definitions for the reporting of antimicrobial susceptibility.
RESULTS
RESULTS
Antimicrobial susceptibility category agreement in each year was ≥91%. Discrepancies in susceptibility categories were generally because the MICs for EQA panel isolates were on or very close to the susceptibility or resistance breakpoints. A high proportion of isolates tested over the 10 years were within one (≥90%) or two (≥97%) MIC log
CONCLUSIONS
CONCLUSIONS
The high level of comparability of results in this EQA scheme indicates that high quality data are produced by the Euro-GASP participants and gives confidence in susceptibility and resistance data generated by laboratories performing decentralised testing.
Identifiants
pubmed: 30909883
doi: 10.1186/s12879-019-3900-z
pii: 10.1186/s12879-019-3900-z
pmc: PMC6434634
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
281Subventions
Organisme : European Centre for Disease Prevention and Control
ID : ECDC/2013/015
Références
Indian J Med Res. 2005 Jul;122(1):48-51
pubmed: 16106090
J Antimicrob Chemother. 2006 Sep;58(3):580-6
pubmed: 16807252
J Antimicrob Chemother. 2006 Sep;58(3):587-93
pubmed: 16816397
Epidemiol Infect. 2010 Jan;138(1):69-75
pubmed: 19534842
Int J Antimicrob Agents. 2010 May;35(5):457-60
pubmed: 20188518
Sex Transm Infect. 2010 Nov;86(6):427-32
pubmed: 20940154
Genitourin Med. 1990 Feb;66(1):8-13
pubmed: 2107141
BMJ Open. 2012 Jul 02;2(4):null
pubmed: 22761285
J Clin Microbiol. 2014 May;52(5):1435-40
pubmed: 24554750
Ann Med Health Sci Res. 2014 May;4(3):453-6
pubmed: 24971225
Clin Microbiol Rev. 2014 Jul;27(3):587-613
pubmed: 24982323
J Clin Pathol. 2014 Nov;67(11):1013-6
pubmed: 25078330
Sex Transm Dis. 2014 Dec;41(12):723-9
pubmed: 25581808
J Antimicrob Chemother. 2015 Sep;70(9):2427-39
pubmed: 26089441
BMC Infect Dis. 2015 Aug 11;15:321
pubmed: 26259560
J Clin Microbiol. 2015 Nov;53(11):3646-9
pubmed: 26338862
PLoS One. 2015 Dec 08;10(12):e0143304
pubmed: 26646541
J Med Microbiol. 2016 Jul;65(7):701-702
pubmed: 27221395
Diagn Microbiol Infect Dis. 2016 Sep;86(1):40-3
pubmed: 27342784
J Antimicrob Chemother. 2016 Nov;71(11):3096-3108
pubmed: 27432602
BMC Microbiol. 2016 Oct 10;16(1):236
pubmed: 27724873
Antimicrob Resist Infect Control. 2016 Nov 24;5:46
pubmed: 27904747
Sex Transm Infect. 2017 Nov;93(7):487-492
pubmed: 28360378
BMC Infect Dis. 2017 Sep 11;17(1):617
pubmed: 28893203
Sex Transm Infect. 2018 Nov;94(7):479-482
pubmed: 29674407
Antimicrob Agents Chemother. 1987 Nov;31(11):1744-9
pubmed: 3124737
J Antimicrob Chemother. 1988 Oct;22(4):463-71
pubmed: 3144523
Antimicrob Agents Chemother. 1984 Aug;26(2):192-5
pubmed: 6435514